Related Experiment Video
Updated: Jun 19, 2025
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
O-demethyl galantamine alters protein expression in cerebellum of 5xFAD mice
İrem Kiriş1,2, Merve Karayel Başar1, Büşra Gürel3
1Department of Biochemistry and Molecular Biology, Institute of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, İstanbul, Turkiye.
Background/Aim:
Alzheimer's disease (AD), one of the most common health issues, is characterized by memory loss, severe behavioral disorders, and eventually death. Despite many studies, there are still no drugs that can treat AD or stop it from progressing. Previous in vitro tests showed that O-demethyl galantamine (ODG) might have therapeutic potential owing to its 10 times higher acetylcholinesterase inhibitory activity than galantamine (GAL).
Materials And Methods:
We aimed to assess the effect of ODG at the molecular level in a 12-month-old 5xFAD Alzheimer's mouse model. To this end, following the administrations of ODG and GAL (used as a positive control), protein alterations were investigated in the cortex, hippocampus, and cerebellum regions of the brain. Surprisingly, GAL altered proteins prominently in the cortex, while ODG exclusively exerted its effect on the cerebellum.
Results:
GNB1, GNB2, NDUFS6, PAK2, and RhoA proteins were identified as the top 5 hub proteins in the cerebellum of ODG-treated mice. Reregulation of these proteins through Ras signaling and retrograde endocannabinoid signaling pathways, which were found to be enriched, might contribute to reversing AD-induced molecular changes.
Conclusion:
We suggest that, since it targets specifically the cerebellum, ODG may be further evaluated for combination therapies for AD.
